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Type 2 diabetes (T2D) is associated with vascular dysfunction. We
hypothesized that increased nuclear factor-kB (NF-kB) signaling
contributes to vascular dysfunction in T2D. We treated type 2 di-
abetic (db2/db2) and control (db2/db+) mice with two NF-kB
inhibitors (6 mg/kg dehydroxymethylepoxyquinomicin twice a
week and 500 mg/kg/day IKK-NBD peptide) for 4 weeks. Pres-
sure-induced myogenic tone was signiﬁcantly potentiated, while
endothelium-dependent relaxation (EDR) was impaired in small
coronary arterioles and mesenteric resistance artery from diabetic
mice compared with controls. Interestingly, diabetic mice treated
with NF-kB inhibitors had signiﬁcantly reduced myogenic tone
potentiation and improved EDR. Importantly, vascular function
was also rescued in db2/db2p50NF-kB2/2 and db2/db2PARP-12/2
double knockout mice compared with db2/db2 mice. Additionally,
the acute in vitro downregulation of NF-kB–p65 using p65NF-kB
short hairpin RNA lentivirus in arteries from db2/db2 mice also
improved vascular function. The NF-kB inhibition did not affect
blood glucose level or body weight. The RNA levels for Sp-1 and
eNOS phosphorylation were decreased, while p65NF-kB phos-
phorylation, cleaved poly(ADP-ribose) polymerase (PARP)-1, and
cyclooxygenase (COX)-2 expression were increased in arteries
from diabetic mice, which were restored after NF-kB inhibition
and in db2/db2p50NF-kB2/2 and db2/db2PARP-12/2 mice. In the
current study, we provided evidence that enhanced NF-kB acti-
vity impairs vascular function by PARP-1–, Sp-1–, and COX-2–
dependent mechanisms in male type 2 diabetic mice. Therefore,
NF-kB could be a potential target to overcome diabetes-induced
vascular dysfunction. Diabetes 62:2078–2087, 2013
Diabetes-induced vascular dysfunction is a majorclinical problem that is responsible for mor-bidity and predisposes patients to a variety ofcardiovascular diseases (1,2). Vascular endo-
thelial and smooth muscle cell dysfunction are early events
in diabetes, characterized by impaired nitric oxide (NO)
pathway signaling and potentiation of pressure-induced
myogenic tone (3–6). The loss of vascular endothelial NO
bioavailability in diabetes results in vasospasm, platelet
aggregation, leukocyte adhesion, vascular smooth muscle
proliferation, and induction and progression of atheroscle-
rosis (7–9) associated with increases in activity of the
proinﬂammatory transcription factor nuclear factor-kB (NF-
kB) (7). The activation of the NF-kB pathway regulates
gene expression of cytokines and chemotactic and matrix
proteins and induces cell proliferation resulting in the in-
duction and progression of vascular disease (10).
It has been shown that hyperglycemia induces cyclo-
oxygenase (COX)-2 expression through NF-kB pathway
(11). This concept is supported by previous studies showing
that COX-2 induction is primarily mediated through the ac-
tivation of the NF-kB pathway (12,13). It has been reported
that NF-kB subunits interact with poly(ADP-ribose) poly-
merase (PARP)-1 in the nucleus and then both bind to DNA
to modulate gene expression (14). Recently, we have dem-
onstrated that PARP-1 activity is enhanced in the vascula-
ture in type 2 diabetes and is involved in the impairment of
vascular function (15). It also has been shown that NF-kB
regulates inﬂammatory cytokines through the transcription
factor Sp-1 (16,17). Thus, the role and mechanism of NF-kB
in vascular dysfunction in type 2 diabetes are important
questions that remain unanswered. Therefore, in this study
we determined whether enhanced NF-kB activity impairs
vascular function in type 2 diabetes by PARP-1–,Sp-1–, and
COX-2–dependent mechanisms and conﬁrmed that the ef-
fect of NF-kB is not speciﬁc to one vascular bed by including
coronary and mesenteric resistance arteries (MRAs).
RESEARCH DESIGN AND METHODS
All experiments were performed according to the American Guidelines for the
Ethical Care of Animals and were approved by Tulane University Health
Sciences Center Animal Care and Use Committee. Type 2 diabetic male mice
(db2/db2) (8- to 10-week-old males) and their homologous controls were
purchased from The Jackson Laboratory (Bar Harbor, ME), housed in groups
of ﬁve mice, and maintained at a temperature of 23°C with 12-h light/dark
cycles. Mice were fed on a solid standard diet (Na+ content 0.4%) and water.
Mice were divided into six groups: 1) control mice infused with saline (n = 10),
2) control mice that received dehydroxymethylepoxyquinomicin (DHMEQ)
(an NF-kB inhibitor, 6 mg/kg i.p. injection twice a week) for 4 weeks (n = 10),
3) control mice that received IKK-NBD peptide (an NF-kB inhibitor, 500 mg/kg/
day daily i.p. injection) for 4 weeks (n = 10), 4) db2/db2 mice infused with
saline (n = 10), 5) db2/db2 mice treated with DHMEQ (6 mg/kg i.p. injection
twice per week) for 4 weeks (n = 10), and 6) db2/db2 mice treated with IKK-
NBD peptide (500 mg/kg/day i.p. daily) for 4 weeks (n = 10). The body weight
and blood glucose levels were recorded weekly during the experimental pe-
riod. Blood glucose measurements were obtained from tail blood samples
using a blood glucose meter (Prestige Smart System HDI; Home Diagnostic,
Fort Lauderdale, FL) in all groups of mice after a 6-h fast as previously de-
scribed (18). Systolic blood pressure was measured by the tail-cuff machine as
previously described (19).
At the end of the treatment period, mice were anesthetized with isoﬂurane
and blood samples were collected from carotid artery into containing heparin
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tubes. Then, tissues (heart and MRA) were harvested immediately, placed in
physiological salt solution (PSS) solution (composition in millimoles per liter:
NaCl 118, KCl 4.7, CaCl2 2.5, KH2PO4 1.2, MgSO4x7H2O 1.2, NaHCO3 25, and
glucose 11, pH = 7.4), and processed appropriately for further studies.
In another series of experiments, we used 8-week-old double knockout
between db2/db2 and p-50NF-kB male mice (db2/db2p50NF-kB2/2, n = 5) and
between db2/db2 and PARP-1 male mice (db2/db2PARP-12/2, n = 5). The
PARP-1 knockout mice were provided by A.B. The p50NF-kB knockout mice
were purchased from The Jackson Laboratory. To generate double knockout,
we bred heterozygote db2/db+ with PARP-1 or p50NF-kB knockout mice.
Before the animals were killed, the body weight and blood glucose levels were
measured. Then mice were anesthetized with isoﬂurane and then coronary
arterioles (CAs), and MRAs were immediately harvested, placed in PSS solu-
tion, and processed appropriately for further studies.
To study the metabolic characterization of the mice on drugs and crossed
with knockouts, we measured the insulin and cholesterol levels using the In-
sulin ELISA kit (Mercodia, Uppsala, Sweden) and cholesterol kit (Cayman
Chemical Company, Ann Arbor, MI), respectively. We also measured markers
of inﬂammation (interleukin-6 and tumor necrosis factor [TNF]-a [both Bio-
science, San Diego, CA).
Vascular reactivity
Ex vivo experiments. Diameter. The left anterior descending CAs and MRAs
were isolated, cannulated with glass micropipettes, and perfused with PSS
bubbled with a 95% O2 plus 5% CO2 gas mixture. The vessels were pressurized to
50 mmHg using pressure-servo control perfusion systems (Living Systems
Instruments, St. Albans, VT) for a 40-min equilibration period. The vessel di-
ameter was monitored by a video image analyzer as previously described (19,20).
Intraluminal pressure was increased from 25 to 100 mmHg in a stepwise
manner to measure myogenic tone. At the end of the experiments, vessels were
incubated with a calcium-free PSS to determine passive diameter. Myogenic
tone is calculated as the percentage between active and passive diameter. For
determination of the endothelium-dependent relaxation (EDR), pressurized
arteries were preconstricted with thromboxane agonist (U-46619, 1027 mol/L)
and then cumulative concentrations (1029 to 1025 mol/L) of acetylcholine
(ACh) were assessed. The NO synthase inhibitor NG-nitro-L-arginine methyl
ester (L-NAME) (1024 mol/L) was added to the superfusate for 30 min before
the assessment of the vasodilator response to ACh.
Isometric tension recording. MRAs from control and diabetic mice were
carefully cleaned of fat and connective tissue and then cut into rings (2 mm in
length). MRAs were mounted in a small-vessel dual-chamber myograph for
measurement of isometric tension. After a 30-min equilibration period in PSS
solution bubbled with carbogen at 37°C and pH = 7.4, arteries were stretched
to their optimal lumen diameter for active tension development. After a sec-
ond 30-min equilibration period, the vessels were exposed to phenylephrine
(PE) (1025 mol/L) and the presence of functional endothelium was assessed
by the ability of ACh (1026 mol/L) to induce relaxation.
For determination of the role of endothelial NO synthase (eNOS) and COX-2
in the impaired EDR in diabetic mice, MRAs were incubated with NS 398 (10
mmol/L), a COX-2–selective inhibitor, for 1 h and then EDR was performed
after precontraction with PE. For determination of the role of eNOS and
NADPH oxidase in the impaired EDR in diabetic mice, MRAs were incubated
with L-NAME (100 mmol/L) and apocynin (100 mmol/L) for 30 min and then
EDR was performed after precontraction with PE.
The same protocol was used for double knockout db2/db2 and p50 NF-kB
(db2/db2p50NF-kB2/2) and db2/db2 and PARP-1 (db2/db2PARP-12/2) male mice.
After precontraction with PE (1025 mol/L) and the steady maximal contrac-
tion, cumulative dose-response curves were obtained for ACh (1028 to 1025
mol/L) and sodium nitroprusside (SNP) (1028 to 1025 mol/L) in the presence
or absence of NS-398, L-NAME, and apocynin.
In vitro experiments. MRA and CAs from diabetic mice were carefully
cleaned of fat and connective tissue and then cut into rings (2 mm in length).
Arteries from MRA were mounted in a small-vessel dual-chamber myograph
for measurement of isometric tension. Arteries were incubated with either
p65NF-kB short hairpin RNA (shRNA) lentiviral particle (Santa Cruz Biotech-
nology, Santa Cruz, CA), to downregulate p65NF-kB expression, or AG1478 (LC
Laboratories, Woburn, MA), epidermal growth factor receptor (EGFR) tyrosine
kinase (EGFRtk) inhibitor for 4 h. After precontraction with PE (1025 mol/L)
and the steady maximal contraction, cumulative dose-response curves were ob-
tained for ACh (1028 to 1025 mol/L) and SNP (1028 to 1025 mol/) in the presence
or absence of L-NAME as described above.
Western blot analysis. Freshly isolated hearts MRAs from all groups were
immediately frozen in liquid nitrogen and then homogenized in ice-cold lysis
buffer as previously described (18–20). Western blot analysis was performed
for phosphorylated and total eNOS (1:1,000 dilution; Cell Signaling, Boston,
MA), phosphorylated and total p65NF-kB (1:1,000 dilution; Cell Signaling),
cleaved and total PARP-1 (1:1,000 dilution; Cell Signaling), and COX-2 (1:500
dilution, Santa Cruz Biotechnology) using speciﬁc antibodies. Blots were
stripped and then reprobed with either b-actin (1:2,000 dilution, Santa Cruz
Biotechnology) or glyceraldehyde-3-phosphate dehydrogenase (1:2,000 di-
lution, Santa Cruz Biotechnology) antibodies to verify the equal loading among
the samples.
Endothelial cell culture, transient transfection, and luciferase assays.
Mouse coronary arterial endothelial cells (ECs) were purchased from Celprogen
(San Pedro, CA), and they were cultured according to the manufacturer
instructions using complete growth media. Cultures were incubated at 37°C in
a humidiﬁed 5% CO2 incubator, and the medium was changed every 2 days.
Conﬂuent cell monolayers were harvested by a brief incubation with 0.25%
trypsin-EDTA solution (GIBCO; Invitrogen, Grand Island, NY) and subcultured
to perform further experiments between passages 3 and 7.
ECs were transiently transfected with lipofectamine LTX and Plus trans-
fection reagents (Invitrogen) in 80% conﬂuent 12-well culture dishes, including
1 mg of the reporter plasmid pGL2-eNOSPromoter luciferase containing 1,621-bp
fragment of human eNOS promoter and 0.5 mg of the reporter plasmid pRL-TK
(Promega, Fitchburg, WI) in the presence or absence of 1 mg of the expression
vector pCMV4-p65. The plasmids pGL2-eNOSPromoter and pCMV4-p65 were
purchased from Addgene (cat. nos. 19297 and 21966, respectively). After 48 h of
incubation with normal glucose (5 mmol/L) or high glucose (25 mmol/L), cells
were lysed in lysis buffer (Promega), and luciferase and renilla activities were
measured with the dual Luciferase Assay System (Promega) with a luminometer
(Fluoroskan Ascent FL; Laboratory Systems, Kilsyth, Victoria, Australia). The
renilla activity was used to normalize the transfection efﬁciency. In another set
of experiments, the ECs were only transfected with 1 mg of the expression
vector pCMV4-p65 and incubated with normal or high glucose to isolate RNA for
further experiments.
Real-time PCR. Sp1 and eNOS mRNA levels were determined in heart tissues
and ECs. Total RNA from heart was obtained using the RNeasy Fibrous Tissue
Mini Kit (Quiagen, Valencia, CA) according to the manufacturer’s recom-
mendations or using the TRI Reagent (Sigma-Aldrich, St. Louis, MO) for cells.
A total of 1 mg DNase I–treated RNA was reverse transcribed into cDNA using
the High Capacity cDNA Archive kit (Applied Biosystems, Foster City, CA)
with random hexamers in a 20-mL reaction. PCR was performed in duplicate
for each sample using 1 mL cDNA as a template 31 of TaqMan Universal PCR
Master Mix (Applied Biosystems) and 310 of Taqman Gene Expression
Assays (Applied Biosystems) in a 20-mL reaction. Assays-on-Demand (Applied
Biosystems) of TaqMan ﬂuorescent real-time PCR primers and probes were
used for Sp1 (Mm00489039_m1), Nos3 (Mm00435217_m1), and glyceralde-
hyde-3-phosphate dehydrogenase (Mm99999915_g1), which was used as en-
dogenous control to normalize results. Quantitative RT-PCR was carried out in
an ABI PRISM 7000 Sequence Detection System (Applied Biosystems) using
the following conditions: 2 min at 50°C and 10 min at 95°C followed by 40
cycles of 15 s at 95°C and 1 min at 60°C. Relative mRNA levels were de-
termined using the 2-ΔΔCt method. Results are expressed as the relative ex-
pression of mRNA in treated mice or transfected cells compared with
untreated mice or control cells.
Drugs. PI hydrochloride, ACh, L-NAME, apocynin, and NS398 were obtained
from Sigma-Aldrich. IKK-NBD peptide was purchased from Enzo Lifesciences
(Farmingdale, NY). The DHMEQ was synthesized by K.U. (Aichi Medical
University, Nagakute, Japan).
Statistical analysis. Results are expressed as means 6 SEM. Concentration
response curves were analyzed using the GraphPad Prism 4.0 software
(GraphPad, La Jolla, CA). One-way or two-way ANOVA was used to compare
each parameter when appropriate. Comparisons between groups were per-
formed with t tests when the ANOVA test was statistically signiﬁcant. Values
of P , 0.05 were considered signiﬁcant. Differences between speciﬁed groups
were analyzed using the Student t test (two tailed) for comparing two groups,
with P , 0.05 considered statistically signiﬁcant.
RESULTS
General parameters. Blood glucose levels and body
weight were elevated in diabetic mice (383.1 6 28.8 mg/dL
and 43.3 6 0.6 g, respectively) compared with control
mice (131.1 6 1.8 mg/dL and 25.7 6 0.5 g) but were not
affected by the NF-kB inhibitors or in double knockout
mice (db2/db2p50NF-kB2/2 and db2/db2PARP-12/2), in-
dicating that enhanced NF-kB and PARP-1 activity are in-
volved in type 2 diabetes–induced vascular complication
(Table 1). Systolic blood pressure was similar in all groups
(Table 1).
Insulin levels as well as cholesterol, interleukin-6, and
TNF-a were increased in the diabetic mice compared with
control mice (Figure Suppl. 1). Treatment with either DHMEQ
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or peptide had no effect on the control group. Additionally,
NF-kB inhibitors reduced interleukin-6 levels and TNF-a in the
diabetic group with no effect on insulin and cholesterol. In-
terestingly, all of these parameters were reduced in double
knockout mice (db2/db2p50NF-kB2/2 and db2/db2PARP-12/2)
(Supplementary Fig. 1).
NF-kB and coronary and MRA reactivity. Myogenic
tone was signiﬁcantly increased in the CA and MRA from
diabetic mice compared with control mice and was nor-
malized after NF-kB inhibition (Fig. 1A and B). The EDR
was also impaired in CA and MRAs from diabetic mice and
was rescued after NF-kB inhibition (Fig. 1C and D). To
strengthen our data, we examined myogenic tone and
the EDR in CAs and MRAs from db2/db2 p50NF-kB2/2 and
db2/db2PARP-12/2 double knockout mice. It was observed
that the myogenic tone and EDR in CAs and MRAs were also
normalized in these two double knockout mice (Fig. 1E–H).
We did not observe any effect on myogenic tone or EDR
in CAs or MRAs from control mice treated with DHMEQ
and IKK-NBD peptide (Supplementary Fig. 2A–D). The
inhibition of eNOS with L-NAME reduced the EDR in all
groups of mice (Supplementary Fig. 2E and F).
Effect of acute EGFRtk inhibition and downregulation
of p65NF-kB on CA reactivity. To determine whether NF-
kB is downstream of EGFRtk and that the acute down-
regulation of NF-kB improves coronary vascular function in
diabetes, we incubated CAs from db2/db2 mice with the
EGFRtk inhibitor (AG1478, 1 mmol/L) for 4 h. Our results
show a signiﬁcant improvement in EDR associated with
a reduction in NF-kB activity (Figs. 1I and 2G).
Furthermore, in isolated coronary artery from db2/db2
mice transfected with p65NF-kB shRNA lentiviral particles
for 4 h, there was a signiﬁcant reduction in p65NF-kB
expression and improvement in coronary EDR (Figs. 1J
and 2K). As a control experiment, CA from db2/db2 mice
transfected with scrambled shRNA did not show improved
coronary EDR (Fig. 1J).
NF-kB and signaling. To conﬁrm the effect of NF-kB
inhibition, we performed Western blot analysis and found
that NF-kB activity was elevated in db2/db2 mice com-
pared with db2/db2 mice treated with DHMEQ and IKK-
NBD peptide and compared with the double knockout
db2/db2 p50NF-kB2/2 and db2/db2PARP-12/2 mice (Fig. 2A,
D, and H). The eNOS phosphorylation at Ser 1177 and the
expression were signiﬁcantly reduced in CA from db2/db2
mice compared with controls, db2/db2 mice treated with
DHMEQ and IKK-NBD peptide, and db2/db2 p50NF-kB2/2
and db2/db2PARP-12/2 mice (Fig. 2B, E, and I).
To study the effect of NF-kB inhibition on PARP-1 sig-
naling, we performed Western blot in CA from all groups.
Our data indicate that cleaved PARP-1 levels and total
PARP-1 were increased in the diabetic group compared
with diabetic mice treated with DHMEQ and IKK-NBD
peptide and in double knockout db2/db2 p50NF-kB2/2 and
db2/db2PARP-12/2 mice (Fig. 2C, F, and J).
NF-kB and EDR in MRAs. Figure 3A shows the key
representative curves made in the wire myograph to test
the EDR. Our data demonstrated that EDR is impaired in
MRAs in db2/db2 mice and the inhibition of NF-kB with
DHMEQ and IKK-NBD peptide signiﬁcantly improved the
EDR (Fig. 3B and Supplementary Table 1).
We did not observe a change in EDR in MRA from
control mice treated with DHMEQ and IKK-NBD peptide
(Supplementary Fig. 3A). The inhibition of eNOS with
L-NAME reduced EDR in all groups of mice (Supplemen-
tary Fig. 3B). To further elucidate the mechanism of vas-
cular endothelial dysfunction in diabetic mice related to
NF-kB, we studied the role of the COX-2 and oxidative
stress pathways. Thus, the inhibition of NADPH oxidases
by apocynin showed a signiﬁcant improvement in MRA
(Fig. 3C and Supplementary Table 1). In addition, the COX-
2 inhibition by NS398 signiﬁcantly improved the EDR in
MRA (Fig. 3D and Supplementary Table 1). Western blot
analysis revealed that in MRA from db2/db2 mice, eNOS
activity was signiﬁcantly reduced, while NF-kB and PARP-1
activity and COX-2 expression were signiﬁcantly aug-
mented (Fig. 4A–D). Interestingly, the treatment of db2/db2
mice with NF-kB inhibitors (DHMEQ and IKK-NBD pep-
tide) increased eNOS activity and reduced NF-kB, PARP-1
activity, and COX-2 expression (Fig. 4A–D).
To strengthen our studies, we examined the EDR in MRA
in double knockout mice (db2/db2 p50NF-kB2/2). Western
blot analysis conﬁrmed the absence of p50NF-kB in MRA in
db2/db2 p50NF-kB2/2 mice (Fig. 4G). Furthermore, the EDR
was signiﬁcantly improved in MRA isolated from db2/db2
p50NF-kB2 /2 mice associated with increased eNOS activity
(Figs. 3E and 4E and Supplementary Table 1). To further
determine the mechanism of NF-kB in vascular function, we
studied the role of PARP-1 and COX-2 as downstream sig-
naling for NF-kB. Thus, EDR was signiﬁcantly improved in
double knockout db2/db2PARP-12/2 mice and arteries from
db2/db2 mice treated with COX-2 inhibitor (Fig. 3E and F
and Table 1). These data were also associated with re-
duction in cleaved PARP-1 and COX-2 expression in MRA
from db2/db2 p50NF-kB2/2 mice (Fig. 4I and K). Further-
more, Western blot analysis revealed that in MRA from
db2/d2 PARP-12/2 mice, PARP-1 was absent and this was as-
sociated with reduced p65NF-kB phosphorylation or COX-2
expression or with an increase in eNOS phosphorylation
(Fig. 4F, H, J, and L). Endothelium-independent relaxation
TABLE 1
Blood glucose, body weight, and systolic blood pressure measurements
Body weight (g) Blood glucose (mg/dL) SBP (mmHg)
Control 25.79 6 0.58 131.1 6 1.89** 101.1 6 1.09
Control plus DHMEQ 27.98 6 1.46 145.6 6 5.18** 105.6 6 1.11
Control plus IKK-NBD peptide 25.56 6 0.71 137 6 9.0** 107 6 0.12
db2/db2 43.39 6 0.67* 383.8 6 28.87 103 6 0.87
db2/db2 plus DHMEQ 40.89 6 0.73 409.8 6 28.42 109 6 0.42
db2/db2 plus IKK-NBD peptide 37.86 6 0.2 401 6 24.8 101 6 1.8
db2/db2p50NF-KB2/2 38.50 6 2.90 310.33 6 38.12 103 6 0.12
db2/db2PARP-12/2 39.51 6 4.51 320.12 6 16.24 102 6 1.24
Data are means 6 SE. SBP, systolic blood pressure. *P , 0.05 for db2/db2 vs. control, treated db2/db2, and double knockout; **P , 0.05 for
control vs. db2/db2, treated db2/db2, and double knockout.
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in response to SNP in MRA was similar in control, db2/db2,
and db2/db2 p50NF-kB2/2 mice (Supplementary Fig. 4A).
Effect of acute EGFRtk inhibition and downregu-
lation of p65NF-kB on MRA reactivity. Isolated MRAs
from db2/db2 mice treated with EGFRtk inhibitor signiﬁ-
cantly improved the EDR (Fig. 3G and H and Supple-
mentary Table 1). Western blot analysis conﬁrmed the
reduction in p65NF-kB phosphorylation in MRA (Fig. 4M)
indicating that p65NF-kB is downstream of EGFRtk. The
acute downregulation of p65NF-kB in isolated MRAs from
db2/db2 mice transfected with p65NF-kB shRNA lentiviral
particles signiﬁcantly improved the EDR, which is inhibi-
ted by L-NAME (Fig. 3H and Supplementary Table 1).
Western blot analysis conﬁrmed the downregulation of
p65NF-kB in MRA transfected with p65NF-kB shRNA
lentiviral particles (Fig. 4N). Endothelium-independent
relaxation in response to SNP in MRA showed no differ-
ence between controls, db2/db2, and db2/db2 transfected
with lentivirus shRNA p65NF-kB (Supplementary Fig. 4B).
Effect of high glucose and overexpression of p65NF-
kB on eNOS promoter. To elucidate the mechanism by
which eNOS expression and activity were decreased in di-
abetes, we studied the Sp-1 expression known as down-
stream signaling of NF-kB. Thus, the mRNA levels of Sp-1
were signiﬁcantly reduced in coronary artery isolated from
db2/db2 mice compared with controls (Fig. 5A). In-
terestingly, db2/db2 mice treated with NF-kB inhibitor
signiﬁcantly increased Sp-1 expression in CAs (Fig. 5A). We
did not see any change in Sp-1 expression in control mice
treated with NF-kB inhibitor (Fig. 5A). In primary ECs iso-
lated from CAs, transfected with a reporter plasmid con-
taining the eNOS promoter, the stimulation of these cells
with high glucose and/or overexpression of p65NF-kB sig-
niﬁcantly reduced Sp-1 expression (Fig. 5B). In addition,
eNOS promoter activity was signiﬁcantly reduced in ECs
stimulated with high glucose and/or transfected with
p65NF-kB (Fig. 5C). These results were associated with the
reduction in eNOS expression (Fig. 5D).
FIG. 1. Effect of the NF-KB inhibition on myogenic tone and EDR in coronary and MRAs. Pressure-induced myogenic responses in coronary arteries
and MRAs from control and type 2 diabetic (db2/db2) mice treated with or without DHMEQ and IKK-NBD (IKK) peptide (A and B) and db2/db2
p50NF-KB2/2 and db2/db2PARP-12/2 mice (E and F). *P < 0.05 for db2/db2 vs. control, db2/db2 treated with DHMEQ or IKK-NBD; †P< 0.05 for db2/db2
vs. db2/db2p50NF-KB2/2 and db2/db2PARP-12/2 mice. EDR in response to cumulative doses of ACh (1028 to 1024 mol/L) in coronary arteries and MRAs
from control and db2/db2mice treated with or without DHMEQ and IKK-NBD (C and D) and db2/db2p50NF-kB2/2 and db2/db2PARP-12/2mice (G and H).
*P < 0.05 for db2/db2 vs. control, db2/db2 treated with DHMEQ or IKK-NBD; †P < 0.05 for db2/db2 vs. db2/db2p50NF-KB2/2 and db2/
db2PARP-12/2. EDR in response to cumulative doses of ACh (1028 to 1024 mol/L) in coronary arteries from db2/db2 incubated with either AG1478
(EGFRtk inhibitor) (I) or p65NFkB shRNA lentiviral particle (J). ‡P < 0.05 for db2db2 vs. db2/db2 with AG1478 or db2/db2 with p65NF-kB shRNA
lentiviral particle. PD, passive diameter.
M. KASSAN AND ASSOCIATES
diabetes.diabetesjournals.org DIABETES, VOL. 62, JUNE 2013 2081
DISCUSSION
Our study demonstrates that enhanced NF-kB activity is an
important factor involved in macro- and microvascular
dysfunction in type 2 diabetes. This evidence came from
our ex vivo and in vitro experiments where vascular EDR
and myogenic tone were signiﬁcantly improved in type 2
diabetic mice treated with NF-kB inhibitors and double
knockout mice (db2/db2p50NF-kB2/2 and db2/db2PARP-1)
and with the downregulation of NF-kB using shRNA len-
tiviral particles. We further demonstrated that in diabetes,
NF-kB inhibition improves vascular function by PARP-1–,
Sp-1–, and COX-2–dependent mechanisms. These results
suggest that the NF-kB pathway could be an important
target for a therapeutic approach to reverse diabetes-
induced vascular dysfunction.
In diabetes, vascular complications are major causes for
morbidity and mortality (21–24). Several mechanisms have
been proposed such as hyperglycemia (25), altered COX-2
activity (26), oxidative stress (27), insulin resistance, and
inﬂammation (28). Although previous studies established
the relationship between NF-kB, diabetes, and cardiovas-
cular diseases (29,30), the role and mechanism of NF-kB in
diabetes-induced vascular dysfunction are still unknown.
Myogenic tone is a characteristic of resistance arteries,
which plays an important role in the local regulation of
vascular diameter change and tissue blood ﬂow (31). Pre-
vious studies have investigated impaired small artery and
arteriolar function in diabetic patients and have shown that
vasomotor dysfunction affects both endothelial and smooth
muscle cell–mediated regulatory mechanisms (32,33). In type
2 diabetic mice, we and other investigators have demon-
strated an increase in myogenic tone (15,34,35). Interestingly,
in the current study we observed that the augmented myo-
genic tone in type 2 diabetes is the result of enhanced NF-kB
and PARP-1 activity. Thus, NF-kB and PARP-1 pathway in-
hibition, using pharmacologic and genetic approaches, re-
duced the potentiated myogenic tone in diabetic mice.
Vascular reactivity is also regulated by EDR mechanism.
This mechanism is highly dependent not only on the bio-
availability of NO in large arteries but also on the endothe-
lium-dependent hyperpolarizing factor and prostaglandin
metabolites in resistance arteries (36). Our results indicate
that EDR is impaired in CA and MRA in type 2 diabetes,
which is in agreement with previous studies (31,37,38). It has
been shown that loss of endothelium-derived NO is associ-
ated with increases in NF-kB activity (39). In addition, it has
been reported that cultured porcine coronary EC function is
impaired with senescence, associated with enhanced NF-kB
activity (40). In this study, we demonstrated that type 2 di-
abetes is associated with increased vascular NF-kB activity
and impaired vascular function. Thus, the inhibition of NF-kB
activity with different approaches (pharmacologic, double-
knockout mouse models and downregulation of protein ex-
pression by NF-kB shRNA lentiviral particles) signiﬁcantly
improved EDR in CA and MRA. Importantly, the effect of
NF-kB activity inhibition is not speciﬁc to one vascular bed
FIG. 2. Western blot analysis and quantitative data in homogenized CA from control and type 2 diabetic mice (db2/db2) treated with or without
DHMEQ (DHM) or IKK-NBD (IKK), showing P-p65 and T-p65 (A), P-eNOS and T-eNOS (B), C-PARP-1 and and T-PARP-1 (C), and glyceraldehyde-
3-phosphate dehydrogenase (GAPDH). $P < 0.05 for db2/db2 vs. control, control treated with DHMEQ or IKK-NBD, db2/db2 treated with DHMEQ
or IKK-NBD. #P< 0.05 for db2/db2, db2/db2 treated with DHMEQ or IKK-NBD vs. control, control treated with DHMEQ or IKK-NBD, db2/db2, and
db2/db2p50NF-KB2/2 showing p50 (D), P-eNOS and T-eNOS (E), C-PARP-1 and T-PARP-1 (F), and glyceraldehyde-3-phosphate dehydrogenase.
Control, db2/db2, and db2/db2PARP-12/2, showing P-p-65 and T-p-65 (H), P-eNOS and T-eNOS (I), T-PARP-1 (J), and GAPDH. Control and db2/db2
incubated with either AG1478 (EGFRtk inhibitor) or p65NF-KB shRNA lentiviral particles showing P-p65, T-p65, and GAPDH (G and K).
P, phosphorylated; T, total; C, active.
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FIG. 3. Effect of the NF-kB inhibition on EDR in MRAs. Key representative traces showing EDR curves to ACh from control and type 2 diabetic
mice (db2/db2) treated with or without DHMEQ or IKK-NBD peptide, db2/db2p50NF-kB2/2mice, and db2/db2PARP-12/2) mice (A). EDR in response to
cumulative doses of ACh (1028 to 1025 mol/L) in MRAs precontracted with PE (1025 mol/L) from control and db2/db2 treated with or without
DHMEQ or IKK-NBD peptide (B) and incubated with or without apocynin (Apo) (NADPH oxidase inhibitor) (C) or NS 398 (COX-2 inhibitor) (D).
*P < 0.05 for db2/db2 vs. control, db2/db2 treated with DHMEQ or IKK-NBD. &P < 0.05 for db2/db2 treated with DHMEQ or IKK-NBD vs. control.
EDR in MRA from control, db2/db2, db2/db2p50NF-KB2/2, and db-/db-PARP-12/2 (E) and incubated with COX-2 inhibitor, NS 398 (F), and db2/db2
incubated with either AG1478 (EGFRtk inhibitor) (G) or P65NF-kB shRNA lentiviral particles (H). *P< 0.05 for db2/db2 vs. control, db2/db2p50NF-
KB2/2, or db2/db2PARP-12/2. #P < 0.05 for db2/db2PARP-12/2 vs. control, db2/db2p50NF-KB2/2. $P < 0.05 for db2/db2 vs. db2/db2 plus AG1478. @P <
0.05 for db2/db2, db2/db2 plus scrambled vs. db2/db2 plus p65 shRNA.
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FIG. 4. Western blot analysis and quantitative data in homogenized MRAs from control and type 2 diabetic mice (db2/db2) treated with or without
DHMEQ (DHM) or IKK-NBD (IKK) showing P-eNOS and T-eNOS (A) P-p65, T-p65 (B), c-PARP-1 and T-PARP-1 (C), COX-2 (D), and b-actin. $P <
0.05 for db2/db2 vs. control, control treated with DHMEQ or IKK-NBD, db2/db2 treated with DHMEQ or IKK-NBD. #P < 0.05 for db2/db2, db2/db2
treated with DHMEQ or IKK-NBD vs. control, control treated with DHMEQ or IKK-NBD. Western blot analysis in MRA from control, db2/db2, and
db2/db2p50NFkB2/2) showing P-eNOS, T-eNOS (E), p-50 (G), c-PARP-1 and T-PARP-1 (I and J), COX-2 (K and L), and b-actin and db2/db2PARP-12/2
showing P-eNOS, T-eNOS (F), P-p65 and T-p65 (H), T-PARP-1 (J), COX-2 (L), and b-actin. Western blot analysis in MRA from db2/db2 incubated
with either AG1478 (EGFRtk inhibitor) or p65NF-kB shRNA lentiviral particles, showing P-p65, T-p65 (M and N), and b-actin. P, phosphorylated;
T, total; C, active.
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indicating the critical importance of the NF-kB pathway in
the global regulation of vasculature function in type 2 di-
abetes. It is also interesting to note that NF-kB inhibition did
not reduce blood glucose and insulin levels or body weight,
suggesting that enhanced NF-kB is a consequence of type 2
diabetes.
It is well-known that active NF-kB interacts with PARP-1
and translocates to the nucleus to target promoters (41). In
addition, we previously reported that inhibition of PARP-1
activity improved vascular function in type 2 diabetes (15).
In the current study, we found an increase in PARP-1 ac-
tivity in arteries from type 2 diabetic mice. The inhibition
of PARP-1 activity in db2/db2mice, using genetic deletion,
signiﬁcantly improved vascular function. In addition, the
inhibition of the NF-kB pathway reduced PARP-1 activity,
indicating that NF-kB regulates vascular function in type
2 diabetes by a PARP-1–dependent mechanism. These
results are supported by studies in the literature demon-
strating the formation of a complex NF-kB–PARP-1 in the
nucleus, which binds to DNA to modulate gene expression
(38,42). This activity of this chemical complex is also
supported by our experiments showing an improvement in
vascular function in double knockout db2/db2PARP-12/2
mice.
To further investigate the downstream mechanism of
NF-kB and PARP-1 and because of the importance of the
transcription factor Sp-1 in the regulation of eNOS pro-
moter activity, we studied Sp-1 expression. Interestingly,
we found that Sp-1 mRNA levels were signiﬁcantly re-
duced and were rescued by the inhibition of NF-kB in CAs
from type 2 diabetic mice. In addition, in vitro studies
show that overexpression of p65NF-kB in transfected pri-
mary cultured coronary ECs or incubation with high glu-
cose reduced eNOS promoter activity and eNOS and Sp-1
mRNA levels. Our results are in agreement with studies
indicating that the transcription factor Sp-1 binds to the
eNOS promoter (43). In addition, it has recently been
demonstrated that p65NF-kB subunit interacts with Sp-1
and negatively regulates gene expression (44). Therefore,
our results suggest that enhanced NF-kB signaling impairs
vascular function by PARP-1– and Sp-1–dependent mech-
anisms.
To provide information about the mechanism of im-
paired vascular function caused by enhanced NF-kB ac-
tivity in diabetes, we observed that vascular COX-2
expression was enhanced in db2/db2 mice. These data are
consistent with studies showing the induction of COX-2 in
type 2 diabetes (45,46).
The NF-kB is a ubiquitous family of transcription factors
that also control the expression of genes involved in the
inﬂammatory response, such as COX-2. Our studies showed
that inhibition of NF-kB activity in db2/db2 mice reduced
FIG. 5. The regulation of eNOS activity. Sp-1 mRNA levels in CAs isolated from control and type 2 diabetic mice (db2/db2) untreated or treated
with IKK-NBD (IKK). *P < 0.05 for db2/db2 vs. control, control treated with IKK-NBD, db2/db2 treated with IKK-NBD (A); Sp-1 and eNOS mRNA
levels in ECs fromCAs stimulated with high glucose or overexpressing P65NF-kB. *P< 0.05 for high glucose, p65NF-KB or high glucose plus p65NF-KB
VS. control, #P < 0.05 for high glucose vs. p65-NF-kB or high glucose plus p65NF-kB (B and D); eNOS promoter activity in transfected primary ECs
from CAs stimulated with high glucose or overexpressed with P65NF-kB. *P < 0.05 for high glucose, p65NF-KB, or high glucose plus p65NF-kB vs.
control; #P < 0.05 for high glucose vs. p65NF-kB or high glucose plus p65NF-kB (C). P-GL3basic indicates the cells transfected with the reporter
plasmid alone without containing the eNOS promoter driving luciferase gene expression, and it is used as control of luciferase basal activity.
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COX-2 expression indicating that COX-2 is downstream to
NF-kB. In addition, the in vitro inhibition of COX-2 improves
vascular function in db2/db2 mice. These data indicate that
inhibition of NF-kB improved vascular function by a COX-
2–dependent mechanism.
Although a previous population-based study showed that
COX-2 inhibitors might lead to increase the risk of myo-
cardial infarction in the general population (47), it has been
shown that a post hoc analysis for different coxibs revealed
a signiﬁcant association with incident atrial ﬁbrillation for
etoricoxib but not for celecoxib. These results indicate that
the issue is mostly related to the nature of COX-2 inhibitors
(48).
In summary, our study demonstrates the importance of
NF-kB in the regulation of vascular function in type 2 di-
abetes by PARP-1–, Sp-1–, and COX-2–dependent mecha-
nisms (Supplementary Fig. 5). Therefore, NF-kB could be
a potential target for a novel therapeutic strategy to reverse
diabetes-induced vascular dysfunction.
Novelty and signiﬁcance. Although there are studies in-
volving NF-kB in diabetes, the proposed study is in-
novative, in our opinion, because our approach provided
direct evidence that enhanced NF-kB activity causes vas-
cular dysfunction in terms of myogenic tone and EDR by
PARP-1–, Sp-1– and COX-2–dependent mechanisms in two
different vascular beds. There is a paucity of studies that
explore the role of the NF-kB pathway and the mechanism
(PARP-1, Sp-1, and COX-2) by which type 2 diabetes
impairs the regulation of arteries, which leads to heart
disease.
Emerging evidence from experimental and clinical re-
search indicates that an NF-kB pathway plays pivotal roles
in cardiovascular diseases. Lack of such knowledge is
a fundamental problem because without it, endothelial
dysfunction that causes coronary artery disease will still
present a high risk for myocardial infarction in diabetic
patients. Thus, our ex vivo and in vitro data clearly indicate
an enhanced NF-kB pathway associated with impaired EDR
in three vascular beds. Importantly, the inhibition of NF-kB
activity improves vascular EDR. Thus, in our study we
demonstrated the role of enhanced NF-kB activity in the
dysfunction of vascular EDR by PARP-1–, Sp-1–, and COX-
2–dependent mechanism.
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